Feder: Viloxazine is a norepinephrine reuptake inhibitor, similar to atomoxetine (Strattera), which was approved in 2008. Feder, what is viloxazine and how does it work?ĭr. Mara: And I’m Mara Goverman, a Licensed Clinical Social Worker in Southern California with a private practice. So, Dr. Josh Feder, The Editor-in-Chief of The Carlat Child Psychiatry Report and co-author of The Child Medication Fact Book for Psychiatric Practice. This is another episode from the child psychiatry team. Welcome to The Carlat Psychiatry Podcast. In this podcast, Mara and I will discuss the advantages and disadvantages of viloxazine for children and adolescents with ADHD. The latest issue of The Carlat Child Psychiatry Report includes a News of Note covering this newly approved medication for ADHD. Feder: On April 2 nd, 2021, viloxazine, brand name Qelbree, received FDA approval for the treatment of ADHD in children and adolescents ages 6-17 years old.
0 kommentar(er)
